{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:27:41Z","timestamp":1767979661095,"version":"3.49.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaad.2021.08.031","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:12:27Z","timestamp":1629717147000},"page":"1113-1116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dermatology patients on biologics and certain other systemic therapies should receive a \u201cbooster\u201d messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations"],"prefix":"10.1016","volume":"85","author":[{"given":"Reid Alexander","family":"Waldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2021.08.031_bib2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2\u2014advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.08.031_bib3","doi-asserted-by":"crossref","first-page":"102613","DOI":"10.1016\/j.jaut.2021.102613","article-title":"Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies\u2014a Danish population-based cohort study","volume":"118","author":"Attauabi","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaad.2021.08.031_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.08.031_bib5","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.jaad.2020.10.075","article-title":"Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab","volume":"84","author":"Waldman","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221023707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221023707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:58:55Z","timestamp":1759273135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221023707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0190962221023707"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.08.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatology patients on biologics and certain other systemic therapies should receive a \u201cbooster\u201d messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}